This Growing Biotech Firm is Fighting Viruses in a Unique Way

[Biotech company has a potentially revolutionary antiviral drug where viruses are unlikely to escape!]( We live in a world where viruses are getting stronger and deadlier. What if there was a way to fight these viruses the way antibiotics fight bacteria? One small-cap biotech company has a treatment that was found to have possibly completely cured the lethal RSV infection in mice! This was based on indefinite survival of the animals with no lung pathology. There is currently no treatment for RSV infection making it an opportunistic time to have your eyes on the company. In particular, pediatric RSV infection treatment is an unmet medical need that is of critical importance. Pediatric RSV treatment itself is expected to be a multi-billion-dollar market in the USA alone. And it doesn’t stop at just RSV. The company’s treatment could be used for COVID, the Flu, and other viruses. Why is this biotech company standing out? The company’s treatment solves the greatest problem in antiviral countermeasures; the problem of virus escape. Viruses are known to escape all the current antiviral tools that include vaccines, antibodies, and small chemical drugs. The company’s treatment of viral infections is reminiscent of how penicillin revolutionized the treatment of bacterial infections. It was even found to be substantially superior to three approved anti-influenza drugs, namely, oseltamivir (Tamiflu®, Roche), peramivir (Rapivab®, Biocryst), and baloxavir (Xofluza®, Shionogi/Roche)! [With plenty of cash on hand, discover how this small-cap biotech firm is revolutionizing antiviral therapy and building shareholder value.Â]( Stockguru LLC (dba InvestingDistrict), 2563 cherry hill ln, Hermitage, PA 16148, United States You may [unsubscribe]( or [change your contact details]( at any time.